DYRK1A is definitely a main gene driver of cognitive impairment in DS models, and DYRK1A inhibitors have emerged as a promising therapeutic path to reduce DS cognitive deficits in adults but also after in utero treatment in animal models. Here, DYRK1A is linked to Dravet syndrome.